The study analyzed that Sjögren’s syndrome pipeline comprises of approximately
42 drug candidates in different stages of development. Sjögren’s syndrome is a
chronic inflammatory disease, which leads to infiltration of lacrimal and
salivary glands. It is mostly associated with sicca symptoms, which include dry
eyes (xeropthalmia) and dry mouth (xerostomia). It is also associated with
other autoimmune diseases such as systemic lupus erythematosus and rheumatoid
arthritis. The treatment approaches for this disease mostly include monoclonal
antibodies and small molecules, which are being developed to target and reduce
the inflammatory mediators. Clinical presentation can vary considerably from
relatively mild sicca symptoms, fatigue and arthralgia to severe systemic
symptoms such as glomerulonephritis, vasculitis and a host of neurological
manifestations.
Browse Report Description at: https://www.psmarketresearch.com/market-analysis/sjogrens-syndrome-therapeutics-pipeline-analysis
The positive results of the drug candidates are speeding up the drug
development process for Sjögren’s syndrome. In August 2016, Aldeyra
Therapeutics, Inc. presented the positive Phase II results of NS2, a 1%
dermatologic cream under Phase II stage of development for Sjögren's syndrome.
Six of six (100%) subjects treated with NS2 improved over the course of therapy
as assessed by central review, and the improvement was greater than that
observed among vehicle-treated patients (p < 0.05).
Explore Report Sample
at: https://www.psmarketresearch.com/market-analysis/sjogrens-syndrome-therapeutics-pipeline-analysis/report-sample
Some of the key players developing drugs for Sjögren’s syndrome include
Kissei Pharmaceutical Co., Ltd., UCB Group, Bristol-Myers Squibb Company and
others.
No comments:
Post a Comment